Currently Enrolling Trials
Tibsovo (ivosidenib) - 2 indications
Scroll down for information on each indication:
- for the treatment of patients with acute myeloid leukemia with a susceptible IDH1 mutation; approved July 2018
- for the treatment of patients with IDH1-mutant cholangiocarcinoma; approved August 2021
Tibsovo (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor.
Tibsovo is specifically indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA-approved test with:
- Acute Myeloid Leukemia (AML) - monotherapy or in combination with azacitidine
- Newly-diagnosed AML who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy
- Relapsed or refractory AML
- locally advanced or metastatic cholangiocarcinoma who have been previously treated
Tibsovo is supplied as a tablet for oral administration. The recommended dose is 500 mg taken orally once daily until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response. Administer Tibsovo with or without food. Do not administer Tibsovo with a high-fat meal because of an increase in ivosidenib concentration. Do not split or crush tablets. Administer tablets orally about the same time each day. If a dose of Tibsovo is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours.
Mechanism of Action
Tibsovo (ivosidenib) is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells.
Adverse effects associated with the use of Tibsovo in patients with cholangiocarcinoma may include, but are not limited to, the following:
- abdominal pain
- decreased appetite
Adverse effects associated with the use of Tibsovo in patients with AML may include, but are not limited to, the following:
- electrocardiogram QT prolonged
The Tibsovo drug label comes with the following Black Box Warning: Patients treated with Tibsovo have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.
Indication 1 - for the treatment of patients with acute myeloid leukemia with a susceptible IDH1 mutation
approved July 2018
Clinical Trial Results
The FDA approval of Tibsovo was based on a single-arm trial of 174 adult patients with relapsed or refractory AML with an IDH1 mutation. Tibsovo was given orally at a starting dose of 500 mg daily until disease progression, development of unacceptable toxicity, or undergoing hematopoietic stem cell transplantation. The trial measured the percentage of patients with no evidence of disease and full recovery of blood counts after treatment (complete remission or CR), as well as patients with no evidence of disease and partial recovery of blood counts after treatment (complete remission with partial hematologic recovery or CRh). With a median follow-up of 8.3 months, 32.8% of patients experienced a CR or CRh that lasted a median 8.2 months. Of the 110 patients who required transfusions of blood or platelets due to AML at the start of the study, 37% went at least 56 days without requiring a transfusion after treatment with Tibsovo.
Tibsovo was also evaluated in combination with azacitidinein the global phase 3 AGILE study in patients with previously untreated IDH1-mutated AML. Results from the AGILE trial demonstrated a statistically significant improvement in event-free survival (EFS) and overall survival (OS). The combination resulted in a threefold improvement in median OS (24 months) compared to placebo plus azacitidine (7.9 months) as a first-line treatment for IDH1-mutated AML.
Indication 2 - for the treatment of patients with IDH1-mutant cholangiocarcinoma
approved August 2021
Clinical Trial Results
The FDA approval was based on the ClarIDHy study, a randomized Phase 3 trial for previously treated IDH1-mutated cholangiocarcinoma. Results from the ClarIDHy study demonstrated a statistically significant improvement in the primary endpoint of progression-free survival (PFS) by an independent review committee. The median PFS for Tibsovo and placebo was 2.7 and 1.4 months, respectively. Thirty-two percent and 22% of patients randomized to Tibsovo remained free of progression or death at 6 and 12 months, respectively, versus none on the placebo arm. The study protocol specified that patients randomized to placebo could cross over to Tibsovo at the time of disease progression, and a high proportion of patients in the placebo arm (70.5%) crossed over to Tibsovo . The study also showed the key secondary endpoint of overall survival (OS) favoring patients randomized to Tibsovo compared to those randomized to placebo; however, statistical significance was not reached. OS results are based on the final analysis of OS (based on 150 events which occurred 16 months after the final analysis of PFS. The median OS for Tibsovo was 10.3 months; and placebo was 7.5 months without adjusting for crossover.